At near future and with assistance of artificial intelligence, a new version of CRT I call it "CRT-Hemodynamic" were CRT can measure continuesely contractility, flow, and the rest of hemodynamic, and were the trends would retrieved periodically, and so medications based on that will change automatically. Accordingly, there would be expected improvement in outcomes related to time to event, cost effectiveness, and resource utilizations to determine the change in structure/function/surrogate biomarkers between and within every stage of persistent heart failure. Extensive physiopathology and pharmacology is a must in the core curriculum of training of those interdeciplinary specialties taking care of patients with heart failure.
